[1] Wang H, Zhang J. The glucose metabolic reprogramming in hepatitis B virus infection and hepatitis B virus associated diseases. J Gastroenterol Hepatol, 2023, 38(11):1886-1891. [2] Somnay K, Wadgaonkar P, Sridhar N,et al. Liver fibrosis leading to cirrhosis: Basic mechanisms and clinical perspectives. Biomedicines, 2024, 12(10):2229. [3] Singhal S, M D P, Inuganti S, et al. Percutaneous ultrasound-guided plugged liver biopsy - a single-centre experience. Pol J Radiol, 2021, 86:e239-e245. [4] 姜社甜,闫卫,赵磊,等. 声触诊组织量化技术联合血清肝纤维化指标诊断肝血吸虫病患者肝纤维化效能分析. 实用肝脏病杂志,2025,28(1):124-127. [5] Ikeda Y, Murata A, Nago H,et al. Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B. Hepatol Res, 2024, 54(10):888-898. [6] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 中华肝脏病杂志,2019,27(12):938-961. [7] Jiang K, Mohammad MK, Dar WA,et al. Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients. PLoS One, 2020 , 15(9):e0239624. [8] Wang J, Lu H, Li Q. Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation. Front Immunol, 2024, 15:1414594. [9] 李娟,董先芳,李玲,等. 慢性乙型肝炎患者HBV DNA载量与肝功能、肝纤维化程度及T淋巴细胞亚群的关系. 中华医院感染学杂志,2025,35(4):490-494. [10] 钟雷,章勇,徐芊,等. 慢性乙型肝炎患者microRNA表达及其对肝纤维化分期的诊断价值. 中华医院感染学杂志,2025,35(1):35-39. [11] Wu Y, Xie N, Su G,et al. Optimal techniques for obtaining superior liver specimens at endoscopic ultrasound-guided biopsy: a pilot study on pigs. Gastroenterol Rep (Oxf), 2025, 13:goaf062. [12] Ma HY, Dong L, Quan SZ,et al. Comparison of four markers of hepatic fibrosis and hepatic function indices in patients with liver cirrhosis and hepatoma. Ann Palliat Med, 2021, 10(4):4108-4121. [13] Meier MA, Calabrese D, Suslov A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol, 2021, 75(4):840-847. [14] Cao YT, Xiang LL, Qi F, et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. E Clin Med, 2022, 51:101547. [15] Kim J, Seki E. Hyaluronan in liver fibrosis: basic mechanisms, clinical implications, and therapeutic targets. Hepatol Commun, 2023, 7(4):e0083. [16] 李敏,张丽,曾艾,等. 2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析. 实用肝脏病杂志,2024,27(2):193-197. [17] Shin HE, Kim M, Won CW. Association between plasma procollagen type III N-terminal peptide (P3NP) levels and physical performance in elderly men: The Korean Frailty and Aging Cohort Study (KFACS). Exp Gerontol, 2021, 154:111523. [18] Chen C, Li X, Guolin W. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol, 2021, 22:100300. [19] Ikeda Y, Murata A, Nago H, et al. Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B. Hepatol Res, 2024, 54(10):888-898. [20] Prakash K, Larsson SB, Rydell GE,et al. Analysis of multiple liver explant pieces reveals that levels of hepatitis delta virus RNA are independent of hepatitis B virus expression. Hepatol Commun, 2021, 5(11):1964-1966. [21] Yu HC, Tseng JC, Lu LY,et al. Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy. Eur J Gastroenterol Hepatol, 2021, 33(1):107-113. [22] Fan R, Li G, Yu N,et al. aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in chronic hepatitis B patients. Clin Gastroenterol Hepatol, 2023, 21(12):3070-3079.e13. |